Satralizumab Sustains Eye Bulging Relief for Thyroid Disease
Two phase 3 trials show most early responders kept improvement at 48 weeks, supporting the drug's recent FDA approval for thyroid eye disease.
Updated on Nov. 20, 2026 in Diabetes

Researchers presented 48-week data showing satralizumab maintained improvement in proptosis, or eye bulging, for patients with thyroid eye disease. The results come from two phase 3 trials, SatraGO-1 and SatraGO-2, which included 258 patients with active, moderate-to-severe disease.
Why it matters
The findings add longer-term evidence for satralizumab, the first IL-6 receptor inhibitor approved for thyroid eye disease, which was cleared by the FDA in October 2026. Patients and clinicians weighing treatment options now have follow-up data beyond the initial 24-week period.
The follow-up comes from two phase 3 trials with 258 patients, where about 85% of initial responders kept their eye-bulging improvement at week 48 regardless of later treatment. Whether these gains persist beyond 48 weeks has not been reported, and SatraGO-1 missed statistical significance at week 24.
The players
Satralizumab (Enspryng)
Satralizumab is an IL-6 receptor inhibitor marketed as Enspryng, previously approved for neuromyelitis optica spectrum disorder and now the first drug of its class cleared for thyroid eye disease.
The details
Patients who responded to satralizumab in the first 24 weeks were randomly assigned to continue the drug or switch to placebo, while initial non-responders who had received placebo were moved onto satralizumab. The drug is sold as Enspryng and has previously been used for neuromyelitis optica spectrum disorder.
Timeline
September 2026: Week 24 results were published in Ophthalmology.
October 2026: The FDA approved satralizumab for thyroid eye disease.
Week 48: Follow-up showed sustained proptosis response in initial responders.
Health Landscape
The 48-week follow-up extends the evidence base behind satralizumab's October 2026 FDA approval, the first IL-6 receptor inhibitor cleared for thyroid eye disease. It positions the drug as a newer option alongside existing treatments for an autoimmune condition that affects the tissues behind the eyes.
For patients with thyroid eye disease, the data suggests early improvement from satralizumab may last at least 48 weeks for most responders. Uninsured patients should note that the drug is reported to cost around $18,000 per syringe, while tocilizumab costs one twentieth as much.
The takeaway
Long-term data show most patients who responded early to satralizumab kept their improvement for a year, but cost and the lack of reported outcomes beyond 48 weeks remain important considerations for patients and insurers.
Further reading
Explore more on Diabetes for related endocrine and autoimmune health coverage.
Source note: This article includes information reported by Medscape.



